DURECT (NASDAQ:DRRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of DURECT (NASDAQ:DRRX) in a research note released on Wednesday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

DURECT Stock Down 0.1 %

DURECT stock opened at $0.84 on Wednesday. DURECT has a 52-week low of $0.68 and a 52-week high of $1.88. The firm has a market capitalization of $26.11 million, a price-to-earnings ratio of -1.38 and a beta of 0.94. The firm has a 50-day moving average price of $0.87 and a two-hundred day moving average price of $1.21.

Institutional Trading of DURECT

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC grew its position in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 319,905 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,658 shares during the quarter. Geode Capital Management LLC owned 1.03% of DURECT worth $429,000 as of its most recent filing with the SEC. 28.03% of the stock is currently owned by hedge funds and other institutional investors.

About DURECT

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.